Metagenomi declares MGX-001 DC for hemophilia A; cash $299.9M into 2027

Metagenomi Therapeutics, Inc.

2024-Q2 EPS reported -$1.24 revenue$31,167,000

Declared MGX-001 as lead development candidate for hemophilia A; 12-month NHP data accelerated to September 2024.
Cash, cash equivalents and marketable securities of $299.9M at June 30, 2024; runway into 2027.
R&D expense $28.3M in Q2 2024 vs $22.7M in Q2 2023; G&A expense $8.6M vs $6.6M.
All four Ionis Wave 1 cardiometabolic programs in lead optimization; targeting 1–2 DC nominations in 2025.
Deprioritizing PH1 and ALS programs; pipeline guidance revised through year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.